A discovery program for SARS-CoV-2-nABs potentially targeting its resistant strains.
Is the medical system ready for Alzheimer’s drugs that work?
An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA